Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-7547
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US ; volume:16 ; number:1 ; day:30 ; month:1 ; year:2018 ; pages:1-8 ; date:12.2018
Cost effectiveness and resource allocation ; 16, Heft 1 (30.1.2018), 1-8, 12.2018
- Keyword
-
Atemwegskrankheit
Atemnot
- Contributor
-
Zafari, Zafar
Sadatsafavi, Mohsen
Mark FitzGerald, J.
SpringerLink (Online service)
- DOI
-
10.1186/s12962-018-0089-8
- URN
-
urn:nbn:de:1111-201803261860
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zafari, Zafar
- Sadatsafavi, Mohsen
- Mark FitzGerald, J.
- SpringerLink (Online service)
Other Objects (12)
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
Severe asthma and the omalizumab option
Follicular T Helper and Breg Cell Balance in Severe Allergic Asthma Before and After Omalizumab Therapy
Poster 1012: Safety and efficacy of omalizumab in 10 children with asthma and other allergic comorbidities
Omalizumab in the treatment of severe allergic (IgE-mediated) asthma: an update on recent developments
Cost-effectiveness analysis of dupilumab among patients with uncontrolled severe asthma using LIBERTY ASTHMA QUEST Korean data
Omalizumab in children with severe allergic disease: a case series
Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience
Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study
Population-Based Pharmacodynamic Modeling of Omalizumab in Pediatric Patients with Moderate to Severe Persistent Inadequately Controlled Allergic Asthma
Poster 1014: Omalizumab efficiency in patients with allergic rhinitis and chronic sinusitis
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
Severe asthma and the omalizumab option
Follicular T Helper and Breg Cell Balance in Severe Allergic Asthma Before and After Omalizumab Therapy
Poster 1012: Safety and efficacy of omalizumab in 10 children with asthma and other allergic comorbidities
Omalizumab in the treatment of severe allergic (IgE-mediated) asthma: an update on recent developments
Cost-effectiveness analysis of dupilumab among patients with uncontrolled severe asthma using LIBERTY ASTHMA QUEST Korean data
Omalizumab in children with severe allergic disease: a case series
Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience
Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study
Population-Based Pharmacodynamic Modeling of Omalizumab in Pediatric Patients with Moderate to Severe Persistent Inadequately Controlled Allergic Asthma
Poster 1014: Omalizumab efficiency in patients with allergic rhinitis and chronic sinusitis
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
Severe asthma and the omalizumab option
Follicular T Helper and Breg Cell Balance in Severe Allergic Asthma Before and After Omalizumab Therapy
Poster 1012: Safety and efficacy of omalizumab in 10 children with asthma and other allergic comorbidities
Omalizumab in the treatment of severe allergic (IgE-mediated) asthma: an update on recent developments
Cost-effectiveness analysis of dupilumab among patients with uncontrolled severe asthma using LIBERTY ASTHMA QUEST Korean data
Omalizumab in children with severe allergic disease: a case series
Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience
Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study
Population-Based Pharmacodynamic Modeling of Omalizumab in Pediatric Patients with Moderate to Severe Persistent Inadequately Controlled Allergic Asthma